Loading…
Loading…
Pilot
Hospital buyers love low-risk entry points. This pilot is time-boxed, narrowly scoped, KPI-driven, low-lift, priced to signal seriousness, and trivially convertible to enterprise — with the success threshold defined before day one.
ARKA helps hospital systems turn avoidable advanced-imaging denials into clean, paid claims — cutting denial write-offs on their highest-margin service line by up to 30–40% by documenting medical necessity at the point of order and running the same appropriateness check on the payer side — recovering ~$3.5M/yr for a mid-sized system, without adding headcount.
30–90 days
One service line or one payer — e.g., outpatient MRI/CT for one commercial plan
Fixed pilot fee — credited toward enterprise
Priced to signal seriousness, not to profit. See pricing tiers
Pilot → enterprise: same integration, widen scope; no re-implementation.
Success contract
These metrics are your signed scorecard — baseline, target, and how each is measured. For the full outcomes framework across revenue, efficiency, clinical adoption, and compliance, see outcomes & KPIs.
| KPI | Baseline | Target | How measured |
|---|---|---|---|
| First-pass clean-claim rate | Typical 75–85% on advanced imaging (your rev-cycle baseline) | Material improvement on the scoped cohort vs. baseline | Rev-cycle denial extracts + ARKA validation cohort; weekly pilot readout |
| Advanced-imaging denial rate | 20–40% initial denial on high-cost imaging (industry band) | Material reduction on scoped service line / payer | ROI dashboard denial trend for pilot cohort |
| Auto-clear rate (orders never queued) | 0% without in-flow appropriateness + payer-side check | 35–40% of clearly appropriate orders auto-cleared | INS reviewer queue + validation dashboard auto-clear metrics |
| Prior-auth turnaround time | Manual queue; often beyond CMS-0057-F standard / expedited SLAs | Within simulated CMS-0057-F decision windows (72h expedited / 7 calendar days standard) | Reviewer queue SLA timers + PAS endpoint conformance checks |
| Clinician clicks added | N/A — baseline is zero added workflow | 0 — silent unless a guideline fires | CDS Hooks card delivery logs; champion sign-off during shadow mode |
The pilot instrument is also the research instrument.
Defined jointly up front; if the pilot misses it, month 1 of production is free (existing guarantee).
What happens after day 90? Monthly ops reviews, quarterly business reviews, and shared accountability through production scale — see how success is governed after go-live.
Low risk
Every criterion hospital procurement teams ask for — explicitly met by this offer.
Time-boxed — met
30–90 days with weekly readouts and a fixed end date — not an open-ended evaluation.
Narrowly scoped — met
One department, one payer, or one population — e.g., outpatient MRI/CT for a single commercial plan.
KPI-driven — met
Success metrics co-written before kickoff; the table below is your signed scorecard.
Low-lift — met
Standard CDS Hooks / SMART on FHIR registration — one EHR analyst, light ARKA support; no custom interface engine.
Convertible — met
Same integration widens to enterprise scope — no rip-and-replace when you scale systemwide.
Next step
We co-write the success threshold, align on Phase 0–1 entry criteria, and keep the same integration when you widen to enterprise. Phase 0 paperwork starts on the ARKA Vendor Portal.
ARKA is Non-Device Clinical Decision Support under FD&C Act §520(o)(1)(E). The ordering clinician retains full responsibility for the final decision. Regulatory rationale.
Pilot
Hospital buyers love low-risk entry points. This pilot is time-boxed, narrowly scoped, KPI-driven, low-lift, priced to signal seriousness, and trivially convertible to enterprise — with the success threshold defined before day one.
ARKA helps hospital systems turn avoidable advanced-imaging denials into clean, paid claims — cutting denial write-offs on their highest-margin service line by up to 30–40% by documenting medical necessity at the point of order and running the same appropriateness check on the payer side — recovering ~$3.5M/yr for a mid-sized system, without adding headcount.
30–90 days
One service line or one payer — e.g., outpatient MRI/CT for one commercial plan
Fixed pilot fee — credited toward enterprise
Priced to signal seriousness, not to profit. See pricing tiers
Pilot → enterprise: same integration, widen scope; no re-implementation.
Success contract
These metrics are your signed scorecard — baseline, target, and how each is measured. For the full outcomes framework across revenue, efficiency, clinical adoption, and compliance, see outcomes & KPIs.
| KPI | Baseline | Target | How measured |
|---|---|---|---|
| First-pass clean-claim rate | Typical 75–85% on advanced imaging (your rev-cycle baseline) | Material improvement on the scoped cohort vs. baseline | Rev-cycle denial extracts + ARKA validation cohort; weekly pilot readout |
| Advanced-imaging denial rate | 20–40% initial denial on high-cost imaging (industry band) | Material reduction on scoped service line / payer | ROI dashboard denial trend for pilot cohort |
| Auto-clear rate (orders never queued) | 0% without in-flow appropriateness + payer-side check | 35–40% of clearly appropriate orders auto-cleared | INS reviewer queue + validation dashboard auto-clear metrics |
| Prior-auth turnaround time | Manual queue; often beyond CMS-0057-F standard / expedited SLAs | Within simulated CMS-0057-F decision windows (72h expedited / 7 calendar days standard) | Reviewer queue SLA timers + PAS endpoint conformance checks |
| Clinician clicks added | N/A — baseline is zero added workflow | 0 — silent unless a guideline fires | CDS Hooks card delivery logs; champion sign-off during shadow mode |
The pilot instrument is also the research instrument.
Defined jointly up front; if the pilot misses it, month 1 of production is free (existing guarantee).
What happens after day 90? Monthly ops reviews, quarterly business reviews, and shared accountability through production scale — see how success is governed after go-live.
Low risk
Every criterion hospital procurement teams ask for — explicitly met by this offer.
Time-boxed — met
30–90 days with weekly readouts and a fixed end date — not an open-ended evaluation.
Narrowly scoped — met
One department, one payer, or one population — e.g., outpatient MRI/CT for a single commercial plan.
KPI-driven — met
Success metrics co-written before kickoff; the table below is your signed scorecard.
Low-lift — met
Standard CDS Hooks / SMART on FHIR registration — one EHR analyst, light ARKA support; no custom interface engine.
Convertible — met
Same integration widens to enterprise scope — no rip-and-replace when you scale systemwide.
Next step
We co-write the success threshold, align on Phase 0–1 entry criteria, and keep the same integration when you widen to enterprise. Phase 0 paperwork starts on the ARKA Vendor Portal.
ARKA is Non-Device Clinical Decision Support under FD&C Act §520(o)(1)(E). The ordering clinician retains full responsibility for the final decision. Regulatory rationale.